ABC-DLBCL cells upregulate the expression of some components of BCR signaling, and USP7 inhibition decreases the expression of upregulated parts of BCR signaling and plays an important role in therapeutic targets (Wu et al., 2022a). Here, USP7 is linked to diffuse large B-cell lymphoma.